Effect of inhaled corticosteroids on bone mineral density in patients with asthma.
Journal
Asian Pacific journal of allergy and immunology
ISSN: 0125-877X
Titre abrégé: Asian Pac J Allergy Immunol
Pays: Thailand
ID NLM: 8402034
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
medline:
11
4
2023
pubmed:
18
5
2020
entrez:
18
5
2020
Statut:
ppublish
Résumé
Inhaled corticosteroids (ICS) are a safe treatment for asthma. However, at higher doses, ICS use has been reported to inhibit adrenocortical function. This study aimed to evaluate the effect of ICS on bone mineral density (BMD) in adult patients with asthma. Ultrasonic bone densitometry was performed in 40 patients (14 men, 26 women, mean age 61.2 years, mean duration of asthma 6.19 years) who were receiving ICS for asthma, and the whole bone density, thickness of cortical bone, and density of cancellous bone of the radius was measured. The age-matched mean was set as 100%. Lifetime cumulative dose of ICS was calculated using all past prescriptions. No significant correlations were observed between lifetime cumulative ICS dose and whole bone density (r² = 0.011), cortical bone thickness (r² = 0.022), and cancellous bone density (r² = 0.004). No significant differences were observed between lower and higher lifetime cumulative ICS dose among these BMD parameters (104% vs 97%, 103% vs 99%, and 106% vs 91%, respectively). No significant correlations or differences in lifetime cumulative ICS dose were observed by asthma severity, asthma duration, and pulmonary function. Also, serum markers of bone metabolism showed no significant correlations or differences with lifetime cumulative ICS dose. In the entire study population, long-term ICS use was safe and was not associated with an increased risk of osteoporosis.
Sections du résumé
BACKGROUND
BACKGROUND
Inhaled corticosteroids (ICS) are a safe treatment for asthma. However, at higher doses, ICS use has been reported to inhibit adrenocortical function.
OBJECTIVE
OBJECTIVE
This study aimed to evaluate the effect of ICS on bone mineral density (BMD) in adult patients with asthma.
METHODS
METHODS
Ultrasonic bone densitometry was performed in 40 patients (14 men, 26 women, mean age 61.2 years, mean duration of asthma 6.19 years) who were receiving ICS for asthma, and the whole bone density, thickness of cortical bone, and density of cancellous bone of the radius was measured. The age-matched mean was set as 100%. Lifetime cumulative dose of ICS was calculated using all past prescriptions.
RESULTS
RESULTS
No significant correlations were observed between lifetime cumulative ICS dose and whole bone density (r² = 0.011), cortical bone thickness (r² = 0.022), and cancellous bone density (r² = 0.004). No significant differences were observed between lower and higher lifetime cumulative ICS dose among these BMD parameters (104% vs 97%, 103% vs 99%, and 106% vs 91%, respectively). No significant correlations or differences in lifetime cumulative ICS dose were observed by asthma severity, asthma duration, and pulmonary function. Also, serum markers of bone metabolism showed no significant correlations or differences with lifetime cumulative ICS dose.
CONCLUSIONS
CONCLUSIONS
In the entire study population, long-term ICS use was safe and was not associated with an increased risk of osteoporosis.
Identifiants
pubmed: 32416663
doi: 10.12932/AP-191019-0663
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM